Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “hold” rating reaffirmed by research analysts at Chardan Capital in a report issued on Wednesday, September 13th.
A number of other analysts have also weighed in on the company. ValuEngine raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company assumed coverage on shares of Sage Therapeutics in a research note on Monday, June 12th. They issued an “outperform” rating and a $95.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $82.00 price objective on shares of Sage Therapeutics in a research report on Tuesday, June 13th. BidaskClub upgraded Sage Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 13th. Finally, Leerink Swann reissued an “outperform” rating and set a $97.00 target price (up previously from $90.00) on shares of Sage Therapeutics in a research report on Tuesday, June 20th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $86.77.
Shares of Sage Therapeutics (NASDAQ SAGE) traded down 0.92% during trading on Wednesday, reaching $62.30. The company’s stock had a trading volume of 612,071 shares. The firm’s 50-day moving average price is $80.26 and its 200-day moving average price is $74.83. Sage Therapeutics has a one year low of $38.30 and a one year high of $90.80. The company’s market capitalization is $2.33 billion.
Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same period in the previous year, the business earned ($1.08) earnings per share. On average, equities analysts anticipate that Sage Therapeutics will post ($7.37) earnings per share for the current year.
WARNING: This article was originally reported by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://baseballnewssource.com/markets/sage-therapeutics-inc-sage-given-hold-rating-at-chardan-capital/1642507.html.
A number of institutional investors have recently made changes to their positions in SAGE. FMR LLC boosted its holdings in shares of Sage Therapeutics by 0.3% in the first quarter. FMR LLC now owns 5,590,527 shares of the biopharmaceutical company’s stock valued at $397,319,000 after acquiring an additional 15,451 shares in the last quarter. BlackRock Inc. boosted its holdings in Sage Therapeutics by 5.9% in the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after purchasing an additional 168,424 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Sage Therapeutics by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after purchasing an additional 58,679 shares in the last quarter. State Street Corp increased its position in Sage Therapeutics by 7.7% during the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock worth $96,558,000 after purchasing an additional 87,097 shares during the period. Finally, Palo Alto Investors LLC raised its stake in shares of Sage Therapeutics by 9.1% during the 1st quarter. Palo Alto Investors LLC now owns 1,101,951 shares of the biopharmaceutical company’s stock worth $78,316,000 after buying an additional 92,021 shares in the last quarter.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with our FREE daily email newsletter.